These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 32157419)
1. Pathophysiology and recent therapeutic insights of sickle cell disease. Shah F; Dwivedi M Ann Hematol; 2020 May; 99(5):925-935. PubMed ID: 32157419 [TBL] [Abstract][Full Text] [Related]
2. The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease. Ikuta T; Adekile AD; Gutsaeva DR; Parkerson JB; Yerigenahally SD; Clair B; Kutlar A; Odo N; Head CA Blood Cells Mol Dis; 2011 Dec; 47(4):235-42. PubMed ID: 21945571 [TBL] [Abstract][Full Text] [Related]
3. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Green NS; Barral S Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771 [TBL] [Abstract][Full Text] [Related]
4. The Role of miRNAs as Therapeutic Tools in Sickle Cell Disease. Cyrus C Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684143 [No Abstract] [Full Text] [Related]
5. Induction of fetal hemoglobin in the treatment of sickle cell disease. Fathallah H; Atweh GF Hematology Am Soc Hematol Educ Program; 2006; ():58-62. PubMed ID: 17124041 [TBL] [Abstract][Full Text] [Related]
6. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Green NS; Barral S Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885 [TBL] [Abstract][Full Text] [Related]
9. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease. Hebert N; Rakotoson MG; Bodivit G; Audureau E; Bencheikh L; Kiger L; Oubaya N; Pakdaman S; Sakka M; Di Liberto G; Chadebech P; Vingert B; Pirenne F; Galactéros F; Cambot M; Bartolucci P Am J Hematol; 2020 Nov; 95(11):1235-1245. PubMed ID: 32681733 [TBL] [Abstract][Full Text] [Related]
10. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494 [TBL] [Abstract][Full Text] [Related]
11. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease. De Franceschi L; Franco RS; Bertoldi M; Brugnara C; Matté A; Siciliano A; Wieschhaus AJ; Chishti AH; Joiner CH FASEB J; 2013 Feb; 27(2):750-9. PubMed ID: 23085996 [TBL] [Abstract][Full Text] [Related]
13. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. Okam MM; Ebert BL Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210 [TBL] [Abstract][Full Text] [Related]
14. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Piccin A; Murphy C; Eakins E; Rondinelli MB; Daves M; Vecchiato C; Wolf D; Mc Mahon C; Smith OP Eur J Haematol; 2019 Apr; 102(4):319-330. PubMed ID: 30664257 [TBL] [Abstract][Full Text] [Related]
15. Combined genetic disruption of K-Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in the SAD mouse model of sickle cell disease. Shmukler BE; Rivera A; Bhargava P; Nishimura K; Hsu A; Kim EH; Trudel M; Rust MB; Hubner CA; Brugnara C; Alper SL Blood Cells Mol Dis; 2019 Nov; 79():102346. PubMed ID: 31352162 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells. Chou YC; Chen RL; Lai ZS; Song JS; Chao YS; Shen CK Mol Cell Biol; 2015 Jul; 35(14):2541-53. PubMed ID: 25986606 [TBL] [Abstract][Full Text] [Related]
17. Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data. Rivers A; Jagadeeswaran R; Lavelle D Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R840-R847. PubMed ID: 30067082 [TBL] [Abstract][Full Text] [Related]
18. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Rodgers GP Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195 [TBL] [Abstract][Full Text] [Related]
19. Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood. Meier ER; Byrnes C; Weissman M; Noel P; Luban NL; Miller JL Pediatr Blood Cancer; 2011 Jan; 56(1):103-9. PubMed ID: 21108444 [TBL] [Abstract][Full Text] [Related]
20. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia. Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]